Radiotherapy Induced Oral Mucositis Treatment Market Size & Share 2024 - 2032

Radiotherapy Induced Oral Mucositis Treatment Market Size

Radiotherapy Induced Oral Mucositis Treatment Market size was valued at around USD 2.5 billion in 2023 and is estimated to grow at 4.4% CAGR from 2024 to 2032, driven by the increasing incidence of cancer necessitating radiotherapy coupled with advancements in radiotherapy techniques and a growing focus on supportive care.

According to the latest estimates from the International Agency for Research on Cancer (IARC) in 2022, there were approximately 20 million new cancer cases projecting a rise of over 35 million new cancer cases that by 2050, reflecting a substantial 77% increase from the estimated cases in 2022. Therefore, the increasing prevalence of cancer elevates the demand for cancer treatments such as radiotherapy, consequently boosting the need for remedies targeting oral mucositis and propelling market expansion.
 

Radiotherapy induced oral mucositis treatment refers to therapeutic interventions aimed at managing and alleviating the adverse effects of oral mucositis induced by radiotherapy. This condition characterized by inflammation, ulceration, and pain in the oral mucosa, commonly occurs as a side effect of radiation therapy for head and neck cancer or other types of cancers.
 

Radiotherapy Induced Oral Mucositis Treatment Market Trends

Increasing research activities in the field of radiotherapy-induced oral mucositis treatment by fostering innovation and the development of novel therapies is driving the market growth.
 

• For instance, in May 2023, Soligenix, Inc. received a patent titled "Novel Peptides and Analogs for Use in the Treatment of Oral Mucositis" from the European Patent Office. This patent adds to their existing intellectual property portfolio, which includes patents issued in the U.S., New Zealand, Japan, Australia, and Singapore, as well as numerous pending patent applications in various other jurisdictions globally. These research efforts aim to enhance understanding of mucositis pathophysiology, identify new therapeutic targets, and improve treatment efficacy and patient outcomes.
   
• Therefore, growing research activities along with collaborations between academics, industry, and regulatory bodies contribute to the translation of research findings into clinically relevant interventions, thereby propelling market expansion.
   

Radiotherapy Induced Oral Mucositis Treatment Market Analysis

Based on treatment type, the market is classified into medication and palliative devices. The medication segment is anticipated to acquire the largest market share and sustain its dominance to reach USD 2.3 billion by end of 2032.
 

• The medication segment asserted dominance in the market due to its widespread adoption and effectiveness in treating various conditions. Therefore, availability of diverse range of pharmaceutical products catering to different therapeutic areas will hold a significant share in the market.
   
• Also, topical treatments emerged as the dominant force within the medication segment, driven by their efficacy and direct application to affected areas. The segment offers several drug types targeted to treat various dermatological and mucosal conditions.
   
• Moreover, factors such as ease of administration, rapid onset of action, and minimal systemic side effects contribute to their popularity among patients and healthcare providers. Thus, growing adoption of different medication to treat oral mucositis will spur the market growth.

Learn more about the key segments shaping this market

Download Free PDF

Based on severity, the radiotherapy induced mild oral mucositis treatment market is bifurcated into mild oral mucositis, moderate oral mucositis, and severe oral mucositis (SOM). The moderate oral mucositis segment is projected to hold the largest market share of 42.7% in 2023 and is expected to maintain dominance throughout the analysis period.
 

• The moderate oral mucositis segment encompasses cases where mucositis symptoms are noticeable and impact daily activities but may not be severe enough to require hospitalization or intensive care.
   
• Therefore, treatment modalities such as topical gels, mouthwashes, and systemic medications are commonly prescribed to alleviate pain, reduce inflammation, and promote healing in moderate cases. Thus, the usage of different drugs to treat moderate mucositis will augment the market growth.

North America's radiotherapy induced oral mucositis treatment market accounted for the largest revenue and is anticipated to grow substantially over the analysis period. U.S. dominated the North American market accounting for the highest market revenue of USD 864.4 million in 2023 anticipating significant growth over the analysis period.
 

• North America asserted dominance in the radiotherapy-induced oral mucositis treatment market due to its advanced healthcare infrastructure, significant investments in the oncology field, and a high prevalence of cancer cases.
   
• For instance, according to the article ‘The broadening scope of oral mucositis and oral ulcerative mucosal toxicities of anticancer therapies’ published by American Cancer Society stated that more than 55% of patients with head and neck cancer who were treated with radiotherapy and chemotherapy have oral mucositis, with severe oral mucositis (SOM) affecting approximately 65% of patients. The incidence is influenced by tumor site, radiation field, radiation technique, and the use of concomitant chemotherapy.
   
• Thus, adoption of medications and palliative care to treat oral mucositis is expected to supplement the regional market growth.
   

The UK radiotherapy induced oral mucositis treatment market is expected to witness high growth over the forecast period.
 

• The market growth in the UK is attributed to its comprehensive healthcare services and emphasis on cancer care. Moreover, strong regulatory frameworks and involvement of National Health Service (NHS) ensure the safety and efficacy of treatments, attracting investment and driving innovation in oral mucositis management.
   
• In addition, collaborations between academic institutions and medical centers drive advancements in treatment options, while national healthcare coverage ensures accessibility for patients, thereby anticipating market expansion.
   

Japan gained traction in the Asia Pacific radiotherapy induced oral mucositis treatment market anticipating substantial growth during the analysis period.
 

• The country's aging population and elevated rates of cancer incidence foresee a substantial uptake in treatments, with the escalating occurrence of oral mucositis, thereby adding momentum to market expansion.
   
• Government support for R&D initiatives to cater to the patient's need for novel treatment options further stimulates market expansion.
   
• Moreover, comprehensive supportive care services and favorable reimbursement policies further bolster the country level market growth.
   

China holds a dominant position in the Asia Pacific radiotherapy induced oral mucositis treatment market accounting for the largest market share.
 

• China emerged as a key market for oral mucositis treatment due to the rapidly evolving healthcare sector and increasing investments in cancer care. Also, growing awareness pertaining to supportive care measures and rising cancer burden drive demand for effective therapies, thereby leading to market growth.
   

Radiotherapy Induced Oral Mucositis Treatment Market Share

The market is characterized by numerous players competing for market share. The companies consistently prioritize innovation, product differentiation, marketing strategies, and regulatory compliance to cater to the market demands. Moreover, mergers, acquisitions, and partnerships are common strategies adopted by companies to strengthen their position in the market.
 

Radiotherapy Induced Oral Mucositis Treatment Market Companies

Some of the prominent players operating in the radiotherapy induced oral mucositis treatment industry include:

• Amgen Inc.
• Aurora BioScience
• Colgate-Palmolive Company
• Galera Therapeutics
• Enzychem Lifesciences Corporation
• EpicentRx
• Izun Pharmaceuticals
• MuReva Phototherapy Inc. 
• Solasia Pharma K.K.
• Soligenix Inc.
   

Radiotherapy Induced Oral Mucositis Treatment Industry News:

• In March 2023, EpicentRx, Inc. announced that the U.S. Food and Drug Administration (FDA) granted Fast Track Designation to RRx-001. This direct NLRP3 inhibitor and Nrf2 upregulator possess anti-inflammatory and antioxidant properties, targeting severe oral mucositis in chemotherapy and radiation-treated head & neck cancer patients. The fast-track designation aimed to accelerate the development of a potential treatment for of oral mucositis.
   
• In February 2023, Galera Therapeutics, Inc. received approval by the U.S. FDA to file and receive priority review for the New Drug Application (NDA) for Avasopasem manganese. This drug is intended for the treatment of radiotherapy-induced severe oral mucositis (SOM) in patients undergoing standard-of-care treatment for head and neck cancer. The approval marks a significant advancement in providing an innovative treatment option specifically approved for SOM in head and neck cancer patients.
   

The radiotherapy induced oral mucositis treatment market research report includes an in-depth coverage of the industry with estimates & forecast in terms of revenue in USD Million from 2021 – 2032 for the following segments:

Click here to Buy Section of this Report

Market, By Treatment Type

• Medication
  • Drugs
    • Topical treatments
      • Antibiotics
      • Antifungal
      • Anti-inflammatory
      • Anti-neoplastic
    • Systemic treatments
  • Distribution channel
    • Hospital pharmacies
    • Retail pharmacies
    • Online pharmacies
• Palliative device
  • Type
    • Low-level laser therapy (LLLT) devices
    • Oral cryotherapy systems
    • Other palliative devices
  • End-user
    • Hospitals
    • Specialty clinics
    • Cancer treatment centers
    • Other end-users

Market, By Severity Type

• Mild oral mucositis
• Moderate oral mucositis
• Severe oral mucositis (SOM)

The above information is provided for the following regions and countries:

• North America
  • U.S.
  • Canada
• Europe
  • Germany
  • UK
  • France
  • Spain
  • Italy
  • Netherlands
  • Rest of Europe
• Asia Pacific
  • Japan
  • China
  • India
  • Australia
  • South Korea
  • Rest of Asia Pacific
• Latin America
  • Brazil
  • Mexico
  • Rest of Latin America
• Middle East and Africa
  • Saudi Arabia
  • South Africa
  • UAE
  • Rest of Middle East and Africa